Company intelligence / Profile preview

Sift Biosciences

Cambridge, England, United Kingdomsiftbios.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Shift has developed an AI-driven platform to identify gene targets that modulate cellular aging. Their high-throughput system has uncovered over a hundred genes with potential rejuvenating effects in vitro. Clinical results are not yet available; the company remains at the discovery/preclinical stage.[1][3]

Therapeutic areas: Other
Modalities: Gene therapy (rejuvenation gene-factors)Cellular reprogramming (Yamanaka factors, simulation-guided interventions)
Industry: Biotech

Partnerships

Seeking partners for asset development across age-driven indications[1].Collaboration with academic experts such as Professor Bo Wang, University of Toronto/Vector Institute[2].

Beyond the preview

Go deeper on Sift Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sift Biosciences.

Explore the full profile